We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+8.67%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
-$198M
Cap. Flow
-$346M
Cap. Flow %
-10.98%
Top 10 Hldgs %
41.12%
Holding
79
New
11
Increased
20
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$70.4M
2
MBX
MBX Biosciences
MBX
+$69M
3
IMVT icon
Immunovant
IMVT
+$43.2M
4
ORKA
Oruka Therapeutics
ORKA
+$43M
5
GH icon
Guardant Health
GH
+$42.5M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$180M
2
INSM icon
Insmed
INSM
+$134M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$122M
4
AXSM icon
Axsome Therapeutics
AXSM
+$86.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$71.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Miscellaneous 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
51
Pyxis Oncology
PYXS
$279M
$15.4M 0.49%
4,184,100
– –
CNTX icon
52
Context Therapeutics
CNTX
$34.8M
$14.5M 0.46%
7,419,355
– –
HELP
53
Cybin Inc
HELP
$984M
$13.6M 0.43%
1,529,987
-1
-0% -$10
ZURA icon
54
Zura Bio
ZURA
$442M
$13.3M 0.42%
3,283,783
– –
IVVD icon
55
Invivyd
IVVD
$237M
$11.2M 0.35%
10,953,937
– –
CLYM
56
Climb Bio
CLYM
$810M
$11M 0.35%
2,169,143
-1,735,642
-44% -$12.3M
INO icon
57
Inovio Pharmaceuticals
INO
$119M
$10.4M 0.33%
1,804,366
-262,354
-13% -$2.16M
AVTX icon
58
Avalo Therapeutics
AVTX
$889M
$9.19M 0.29%
+967,000
New +$9.97M
NMRA icon
59
Neumora Therapeutics
NMRA
$145M
$7.5M 0.24%
+567,428
New +$6.62M
TVTX icon
60
Travere Therapeutics
TVTX
$5.98B
$7.44M 0.24%
531,857
-6,838,143
-93% -$71.2M
VIGL
61
DELISTED
Vigil Neuroscience
VIGL
$5.28M 0.17%
1,553,996
+956,781
+160% +$3.54M
RGLS
62
DELISTED
Regulus Therapeutics
RGLS
$5.12M 0.16%
3,262,564
– –
ALLK
63
DELISTED
Allakos
ALLK
$3.27M 0.1%
5,000,000
– –
ANRO icon
64
Alto Neuroscience
ANRO
$1.18B
$2.51M 0.08%
219,648
-292,038
-57% -$3.57M
NMRA icon
65
CALL
Neumora Therapeutics
NMRA
$145M
$2.38M 0.08%
180,500
– –
PRTA icon
66
Prothena Corp
PRTA
$423M
$2.34M 0.07%
+140,000
New +$3.01M
RLMD icon
67
Relmada Therapeutics
RLMD
$450M
$2.19M 0.07%
674,833
-559,940
-45% -$1.81M
ALGS icon
68
Aligos Therapeutics
ALGS
$31.5M
$2.11M 0.07%
244,110
-1
-0% -$12
SYRS
69
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.78M 0.06%
828,485
– –
MGX icon
70
Metagenomi Therapeutics
MGX
$43.4M
$667K 0.02%
307,500
-158,732
-34% -$551K
SRRK icon
71
Scholar Rock
SRRK
$6.01B
$385K 0.01%
48,100
-324,459
-87% -$2.85M
AGEN
72
Agenus
AGEN
$326M
– –
-313,359
Closed -$5.25M
ALNY icon
73
Alnylam Pharmaceuticals
ALNY
$32B
– –
-500,000
Closed -$122M
AMGN icon
74
Amgen
AMGN
$203B
– –
-575,000
Closed -$180M
COGT icon
75
Cogent Biosciences
COGT
$5.65B
– –
-308,235
Closed -$2.6M
1 2
3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Deep Track Capital held 79 positions worth $3.15B, down 5.9% from $3.35B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital withdrew a net $346M in Q3 2024, closing 8 positions and reducing 24 holdings. Its most notable exit was Amgen, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Deep Track Capital opened a new position in MBX Biosciences worth $78.4M.

  • Deep Track Capital's largest Q3 2024 buy was MBX Biosciences: 3,018,935 shares worth $78.4M.
  • Deep Track Capital added most to Apellis Pharmaceuticals in Q3 2024, an estimated $70.4M increase.
  • Deep Track Capital's biggest Q3 2024 reduction was Axsome Therapeutics, cutting an estimated $86.9M.
  • Deep Track Capital fully exited Amgen in Q3 2024, selling an estimated $180M.
  • Deep Track Capital's ten largest holdings make up 41% of its $3.15B portfolio in Q3 2024.
  • Deep Track Capital opened 11 new positions and closed 8 in Q3 2024.
  • Deep Track Capital's portfolio value fell 5.9% quarter-over-quarter to $3.15B.

Based on Deep Track Capital's 13F filing for Q3 2024, filed 14 Nov 2024.